Katharina Feil

Dr. Katharina Feil

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2021 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Open access
PDF file
KVKilian Vomstein
Kilian Vomstein
AAAnna Aulitzky
Anna Aulitzky
LSLaura Strobel
Laura Strobel
MBMichael Bohlmann
Michael Bohlmann
KFKatharina Feil
Katharina Feil
BTBettina Toth
Bettina Toth
While roughly 30% of all women experience a spontaneous miscarriage in their lifetime, the incidence of recurrent (habitual) spontaneous miscarriage is 1 – 3% depending on the employed definition. The established risk factors include endocrine, anatomical, infection-related, genetic, haemostasis-related and immunological factors. Diagnosis is made more difficult by the sometimes diverging recommendations of the respective international specialist societies. The present study is therefore intended to provide a comparison of existing international guidelines and recommendations. The guidelines of the ESHRE, ASRM, the DGGG/OEGGG/SGGG and the recommendations of the RCOG were analysed. It was shown that investigation is indicated after 2 clinical pregnancies and the diagnosis should be made using a standardised timetable that includes the most frequent causes of spontaneous miscarriage. The guidelines concur that anatomical malformations, antiphospholipid syndrome and thyroid dysfunction should be excluded. Moreover, the guidelines recommend carrying out pre-conception chromosomal analysis of both partners (or of the aborted material). Other risk factors have not been included in the recommendations by all specialist societies, on the one hand because of a lack of diagnostic criteria (luteal phase insufficiency) and on the other hand because of the different age of the guidelines (chronic endometritis). In addition, various economic and consensus aspects in producing the guidelines influence the individual recommendations. An understanding of the underlying decision-making process should lead in practice to the best individual diagnosis and resulting treatment being offered to each couple.

27 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ABAnne-Sophie Braun
Anne-Sophie Braun
KVKilian Vomstein
Kilian Vomstein
ERElisabeth Universität Reiser
Elisabeth Universität Reiser
STSusanne Tollinger
Susanne Tollinger
CKChristiana Kyvelidou
Christiana Kyvelidou
BTBettina Toth
Bettina Toth
Background: RPL and RIF are challenges in reproductive medicine. The immune system plays a pivotal role in endometrial receptivity, successful implantation, and pregnancy complications. Immunological changes have been associated with RPL and RIF. Understanding immune dysregulation especially in NK and T cell subtypes may lead to better diagnostic concepts and treatments. From July 2019 to August 2020 patients with RPL and RIF underwent a standardized diagnostic procedure including endometrial biopsies. Immune cell analysis was performed using flow cytometry. Patients were contacted in March 2023 and interviewed concerning their pregnancy outcomes following diagnostics. Results: Out of 68 patients undergoing endometrial biopsies, 49 patients were finally included. Live birth rates were high with 72% in RPL and 86% in RIF. Immune cell analysis revealed that patients with RPL had more cytotoxic CD56dimCD16high cells, while RIF patients had more CD56+ uNK cells. RPL patients with pregnancy complications showed increased NKT cell percentages. Conclusion: Our findings suggest specific immune changes in RPL and RIF patients, offering potential therapeutic targets. Tailored immunotherapy based on endometrial immunophenotyping might be an option, but further research is needed.

25 July 2022 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
KFKatharina Feil
Katharina Feil
DRDavid Riedl
David Riedl
LGLisa Gschwentner
Lisa Gschwentner
KVKilian Vomstein
Kilian Vomstein
JWJulia Wegscheider
Julia Wegscheider
BTBettina Toth
Bettina Toth
Purpose: Quality of life (QoL) is a complex term, including mental, physical and social health, and everyone’s individual environment. While transgender individuals still often report lower QoL than other individuals, they can benefit substantially from gender affirming therapy. The aim of this study was to develop a questionnaire to determine QoL in transgender individuals during gender affirming hormone therapy (GAHT). Methods: A multi-step questionnaire development process was performed. In phase 1, a list of key issues was established by reviewing relevant literature. In phase 2, n = 38 transgender individuals as well as n = 6 practitioners evaluated the questionnaire (iTransQoL) in terms of relevance, meaning, comprehensibility and redundancy. Psychometric testing of the questionnaire was performed in phase 3 with n = 40 transgender individuals. The external validity of the iTransQoL was tested by comparison with three validated health questionnaires. Results: The exploratory factor analysis indicated an underlying four-factor solution. Psychometric testing showed acceptable to good overall reliability (α = 0.73–0.83) for the total score and the four subscales as well as good validity indices. Based on the results, a final version of the iTransQoL was established. Conclusion: The iTransQoL is a reliable and valid tool to evaluate QoL of transgender individuals during GAHT.

6 May 2022 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Open access
PDF file
ABAnne-Sophie Braun
Anne-Sophie Braun
KFKatharina Feil
Katharina Feil
ERElisabeth Reiser
Elisabeth Reiser
GWGuenter Weiss
Guenter Weiss
TSThore von Steuben
Thore von Steuben
BTBettina Toth
Bettina Toth
Background As the COVID-19 pandemic persists and new vaccines are developed, concerns among the general public are growing that both infection with the SARS-CoV-2 virus and vaccinations against the coronavirus (mRNA vaccines) could lead to infertility or higher miscarriage rates. These fears are voiced particularly often by young adults of reproductive age. This review summarizes the current data on the impact of SARS-CoV-2 infection and corona vaccinations on female and male fertility, based on both animal models and human data. Method A systematic literature search (PubMed, Embase, Web of Science) was carried out using the search terms “COVID 19, SARS-CoV-2, fertility, semen, sperm, oocyte, male fertility, female fertility, infertility”. After the search, original articles published between October 2019 and October 2021 were selected and reviewed. Results Despite the use of very high vaccine doses in animal models, no negative impacts on fertility, the course of pregnancy, or fetal development were detected. In humans, no SARS-CoV-2 RNA was found in the oocytes/follicular fluid of infected women; similarly, no differences with regard to pregnancy rates or percentages of healthy children were found between persons who had recovered from the disease, vaccinated persons, and controls. Vaccination also had no impact on live-birth rates after assisted reproductive treatment. No viral RNA was detected in the semen of the majority of infected or still infectious men; however, a significant deterioration of semen parameters was found during semen analysis, especially after severe viral disease. None of the studies found that corona vaccines had any impact on male fertility. Discussion Neither the animal models nor the human data presented in recent studies provide any indications that fertility decreases after being vaccinated against coronavirus. However, there is a growing body of evidence that severe SARS-CoV-2 infection has a negative impact on male fertility and there is clear evidence of an increased risk of complications among pregnant women with SARS-CoV-2 infection. The counseling offered to young adults should therefore take their fears and concerns seriously as well as providing a structured discussion of the current data.

14 June 2023 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
KRKaroline Riess
Karoline Riess
AZAnna Lena Zippl
Anna Lena Zippl
LRLena Reh
Lena Reh
KFKatharina Feil
Katharina Feil
BTBettina Toth
Bettina Toth
Background: The number of individuals who are underweight as well as overweight is increasing worldwide and is known to lead to menstrual disorders and subfertility. Data regarding the prevalence of infertility in Austrian women are lacking. This study aimed to determine the prevalence of a pathologically low and high body mass index (BMI) in Austrian patients with infertility and to evaluate the live birth rate (LBR) after assisted reproductive technologies (ARTs) compared with normal weight patients. Methods: A total of 585 couples with infertility who sought treatment at a single center between April 2017 and April 2019 were included in this retrospective study. The patients were categorized into study group 1 (BMI 30 kg/m2, n = 40), and control group (BMI 19–30 kg/m2, n = 95. They were randomly selected from the n = 522 women within these BMI values). Results: The prevalence rates of BMI 30 kg/m2 were 5.9% and 6.7%, respectively. Baseline clinical and laboratory characteristics as well as the prevalence of pathospermia in their male partners were similar in all study groups. In women undergoing ART (n = 112), LBR was comparable between the study groups (27.3% vs. 31.9% and 22.2%, p = 0.4). Conclusions: The prevalence of low and high BMI in Austrian patients seeking fertility treatment was almost 13%. Although LBR was not reduced, physicians should be more attentive to the BMI values of patients with infertility because pregnancy-related complications are linked to being underweight and obese.

1 February 2026 in Archives of Sexual Behavior
Verified
Journal Article
Open access
KFKatharina Feil
Katharina Feil
TSThessa Seeland
Thessa Seeland
SMSarah Maier
Sarah Maier
DRDavid Riedl
David Riedl
AZAnna Lena Zippl
Anna Lena Zippl
BTBettina Toth
Bettina Toth
This study examined age-related cohort differences in the timing of three key gender identity milestones (first desire to transition, coming out, and initiation of hormone therapy) across gender identities. Data from 212 adult transgender and gender diverse (TGD) individuals (54.2% trans male, 42.5% trans female, 3.3% gender diverse; age 20–76 years) were collected at a single center between 2017 and 2021. Gender diverse participants, defined as those with identities outside the binary, were grouped accordingly. Selected items relating to gender identity milestones and sociodemographic information were drawn from the Innsbruck Quality of Life Questionnaire. Linear regression revealed significant negative correlations between year of birth and age at first desire to transition ( B = − 0.57, p < 0.001), coming out ( B = − 0.77, p < 0.001), and hormone therapy initiation ( B = − 0.89, p < 0.001), indicating earlier milestone attainment in later birth cohorts. Logistic regression showed that earlier birth year significantly predicted higher odds of identifying as a trans woman (OR = 0.95, p < 0.001). Analysis of birth year distribution by gender identity further indicated an increasing trend in individuals seeking hormone therapy, with younger birth years more prevalent among trans men. An association was demonstrated between year of birth and time spans between gender identity milestones, showing a shortening in time intervals in younger participants. Educational attainment in the study cohort was lower than in the general Austrian population. These findings suggest a temporal shift toward earlier realization and affirmation of gender identity among TGD individuals.